SCHEMBL4175553

SCHEMBL4175553

O=S(=O)(CCCl)c1ccc(F)cc1F

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.45
CCR2 P41597 5/20 0.41
AKR1B1 P15121 2/20 0.41
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
POLB P06746 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
KDM2B Q8NHM5 1/20 0.35
AHR P35869 1/20 0.35
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
PKM P14618 1/20 0.34
PKLR P30613 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL776801 0.79 AKR1B1 (0.44) CA2CCR2AKR1B1PSEN1PSEN2
SCHEMBL23358180 0.77 AKR1B1 (0.42) CA2CCR2AKR1B1PSEN1PSEN2
SCHEMBL4178510 0.77 KCNA5 (0.40) CA2AKR1B1
SCHEMBL776555 0.74 AKR1B1 (0.41) CA2CCR2AKR1B1PSEN1PSEN2
SCHEMBL29391243 0.74 AKR1B1 (0.41) CA2CCR2AKR1B1PSEN1PSEN2
SCHEMBL29899701 0.74 AKR1B1 (0.46) CCR2AKR1B1POLBALDH1A1MAPT
SCHEMBL113810 0.74 AKR1B1 (0.46) CCR2AKR1B1POLBALDH1A1MAPT
SCHEMBL778076 0.73 AKR1B1 (0.58) CCR2AKR1B1POLBALDH1A1MAPT
SCHEMBL1980894 0.73 CES2 (0.41) CA2CCR2AKR1B1CES2CES1
SCHEMBL7960579 0.73 PPME1 (0.41) CA2CCR2AKR1B1PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084470-B2 Substituted nicotinamide compounds and uses thereof GRUENENTHAL GMBH (DE) 2011-12-27 US disclosed
US-20090076086-A1 SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF GRUENENTHAL GMBH (DE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076086-A1 SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF NNT, NAMPT, NADK CA2 1545/4885CCR2 2916/4885AKR1B1 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.